1. Home
  2. NZF vs ALMR Comparison

NZF vs ALMR Comparison

Compare NZF & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Credit Income Fund

NZF

Nuveen Municipal Credit Income Fund

HOLD

Current Price

$11.86

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Alamar Biosciences Inc. Common Stock

ALMR

Alamar Biosciences Inc. Common Stock

N/A

Current Price

$29.95

Market Cap

2.1B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
NZF
ALMR
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
2001
2026

Fundamental Metrics

Financial Performance
Metric
NZF
ALMR
Price
$11.86
$29.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
521.5K
338.8K
Earning Date
01-01-0001
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.81
$21.58
52 Week High
$13.22
$38.54

Technical Indicators

Market Signals
Indicator
NZF
ALMR
Relative Strength Index (RSI) 31.18 47.95
Support Level $11.84 $29.15
Resistance Level $12.76 $35.74
Average True Range (ATR) 0.12 2.02
MACD -0.04 -0.60
Stochastic Oscillator 5.30 11.16

Price Performance

Historical Comparison
NZF
ALMR

About NZF Nuveen Municipal Credit Income Fund

Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.

About ALMR Alamar Biosciences Inc. Common Stock

Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

Share on Social Networks: